(KBH) KB Home - Overview
Stock: Residential Homes, Townhomes, Condominiums, Mortgage, Insurance, Title
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.09% |
| Yield on Cost 5y | 2.40% |
| Yield CAGR 5y | 13.62% |
| Payout Consistency | 87.9% |
| Payout Ratio | 16.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 36.0% |
| Relative Tail Risk | -5.18% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.11 |
| Alpha | -18.47 |
| Character TTM | |
|---|---|
| Beta | 0.590 |
| Beta Downside | 0.377 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.66% |
| CAGR/Max DD | 0.45 |
Description: KBH KB Home January 11, 2026
KB Home (NYSE:KBH) is a U.S. homebuilder that markets attached and detached single-family homes, townhomes, and condos across four geographic segments-West Coast, Southwest, Central, and Southeast-targeting first-time, move-up, and active-adult buyers. The firm also offers ancillary financial services, including mortgage origination, title, and various property-insurance products, to streamline the purchase process for homebuyers.
In FY 2023 KB Home delivered 13,600 homes and generated $9.3 billion in revenue, with an average selling price of $363 k, reflecting a 12% year-over-year increase driven by rising construction costs and a tight housing inventory. The company’s backlog stood at roughly 7,200 units, providing visibility into near-term earnings, while its mortgage-originations unit contributed about 3% of total net income, highlighting the strategic value of bundled financing in a high-rate environment. Key sector drivers include the Federal Reserve’s policy on interest rates, labor-market tightness affecting construction labor costs, and regional migration trends that continue to favor Sun Belt markets where KB Home has a strong footprint.
For a deeper, data-rich analysis of KB Home’s valuation dynamics, you may find ValueRay’s platform useful.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 428.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.34 > 1.0 |
| NWC/Revenue: 78.58% < 20% (prev 80.69%; Δ -2.11% < -1%) |
| CFO/TA 0.05 > 3% & CFO 338.6m > Net Income 428.8m |
| Net Debt (1.50b) to EBITDA (592.4m): 2.54 < 3 |
| Current Ratio: 4.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.0m) vs 12m ago -13.41% < -2% |
| Gross Margin: 18.88% > 18% (prev 0.21%; Δ 1867 % > 0.5%) |
| Asset Turnover: 91.32% > 50% (prev 99.91%; Δ -8.59% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z'' 8.47
| A: 0.73 (Total Current Assets 6.27b - Total Current Liabilities 1.37b) / Total Assets 6.72b |
| B: 0.54 (Retained Earnings 3.63b / Total Assets 6.72b) |
| C: 0.08 (EBIT TTM 554.2m / Avg Total Assets 6.83b) |
| D: 1.31 (Book Value of Equity 3.70b / Total Liabilities 2.82b) |
| Altman-Z'' Score: 8.47 = AAA |
Beneish M -2.86
| DSRI: 1.03 (Receivables 356.2m/382.9m, Revenue 6.24b/6.93b) |
| GMI: 1.13 (GM 18.88% / 21.34%) |
| AQI: 1.14 (AQ_t 0.05 / AQ_t-1 0.04) |
| SGI: 0.90 (Revenue 6.24b / 6.93b) |
| TATA: 0.01 (NI 428.8m - CFO 338.6m) / TA 6.72b) |
| Beneish M-Score: -2.86 (Cap -4..+1) = A |
What is the price of KBH shares?
Over the past week, the price has changed by +6.34%, over one month by +6.99%, over three months by +1.29% and over the past year by -6.67%.
Is KBH a buy, sell or hold?
- StrongBuy: 3
- Buy: 1
- Hold: 8
- Sell: 0
- StrongSell: 2
What are the forecasts/targets for the KBH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 61.2 | 0.4% |
| Analysts Target Price | 61.2 | 0.4% |
| ValueRay Target Price | 68.8 | 12.9% |
KBH Fundamental Data Overview February 05, 2026
P/E Forward = 13.5501
P/S = 0.617
P/B = 0.9322
P/EG = 0.63
Revenue TTM = 6.24b USD
EBIT TTM = 554.2m USD
EBITDA TTM = 592.4m USD
Long Term Debt = 1.69b USD (from longTermDebt, last quarter)
Short Term Debt = 350.0m USD (from shortTermDebt, last quarter)
Debt = 1.73b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.50b USD (from netDebt column, last quarter)
Enterprise Value = 5.35b USD (3.85b + Debt 1.73b - CCE 230.4m)
Interest Coverage Ratio = unknown (Ebit TTM 554.2m / Interest Expense TTM 0.0)
EV/FCF = 18.43x (Enterprise Value 5.35b / FCF TTM 290.2m)
FCF Yield = 5.43% (FCF TTM 290.2m / Enterprise Value 5.35b)
FCF Margin = 4.65% (FCF TTM 290.2m / Revenue TTM 6.24b)
Net Margin = 6.88% (Net Income TTM 428.8m / Revenue TTM 6.24b)
Gross Margin = 18.88% ((Revenue TTM 6.24b - Cost of Revenue TTM 5.06b) / Revenue TTM)
Gross Margin QoQ = 17.37% (prev 18.47%)
Tobins Q-Ratio = 0.80 (Enterprise Value 5.35b / Total Assets 6.72b)
Interest Expense / Debt = 1.53% (Interest Expense 26.6m / Debt 1.73b)
Taxrate = 21.44% (27.7m / 129.2m)
NOPAT = 435.4m (EBIT 554.2m * (1 - 21.44%))
Current Ratio = 4.57 (Total Current Assets 6.27b / Total Current Liabilities 1.37b)
Debt / Equity = 0.44 (Debt 1.73b / totalStockholderEquity, last quarter 3.90b)
Debt / EBITDA = 2.54 (Net Debt 1.50b / EBITDA 592.4m)
Debt / FCF = 5.18 (Net Debt 1.50b / FCF TTM 290.2m)
Total Stockholder Equity = 3.97b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.28% (Net Income 428.8m / Total Assets 6.72b)
RoE = 10.80% (Net Income TTM 428.8m / Total Stockholder Equity 3.97b)
RoCE = 9.78% (EBIT 554.2m / Capital Employed (Equity 3.97b + L.T.Debt 1.69b))
RoIC = 7.50% (NOPAT 435.4m / Invested Capital 5.80b)
WACC = 5.95% (E(3.85b)/V(5.58b) * Re(8.09%) + D(1.73b)/V(5.58b) * Rd(1.53%) * (1-Tc(0.21)))
Discount Rate = 8.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -10.12%
[DCF Debug] Terminal Value 80.53% ; FCFF base≈303.5m ; Y1≈199.2m ; Y5≈90.9m
Fair Price DCF = 21.34 (EV 2.85b - Net Debt 1.50b = Equity 1.35b / Shares 63.2m; r=5.95% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -32.31 | EPS CAGR: 1.42% | SUE: -1.74 | # QB: 0
Revenue Correlation: -1.78 | Revenue CAGR: 5.25% | SUE: 0.68 | # QB: 0
EPS next Quarter (2026-05-31): EPS=0.79 | Chg30d=-0.509 | Revisions Net=-7 | Analysts=10
EPS current Year (2026-11-30): EPS=4.20 | Chg30d=-1.922 | Revisions Net=-10 | Growth EPS=-31.7% | Growth Revenue=-11.8%
EPS next Year (2027-11-30): EPS=5.52 | Chg30d=-2.091 | Revisions Net=-3 | Growth EPS=+31.5% | Growth Revenue=+6.6%